Page header

Opinion of the Transparency Council – pomalidomide

At its meeting on 25 November 2024, the Transparency Council adopted opinion No. 182/2024 on changing the reimbursement category of medicinal products with the active substance pomalidomide

 

Publication of the opinion >>